Head-to-head study of GSK’s Votrient® vs sunitinib in advanced renal cell carcinoma meets primary endpoint
1 October 2012 | By GlaxoSmithKline
The pivotal Phase III study COMPARZ has met its primary endpoint...
List view / Grid view
1 October 2012 | By GlaxoSmithKline
The pivotal Phase III study COMPARZ has met its primary endpoint...
1 October 2012 | By Sanofi
Sanofi is pleased to announce the appointment of Dr. Paul Chew...
1 October 2012 | By Roche
Final results from the Phase III HERA trial...
1 October 2012 | By Novartis
Seebri® Breezhaler® approved...
1 October 2012 | By BASF
As of October 1, Scott Thomson will assume the role of Senior Vice President...
28 September 2012 | By Bristol-Myers Squibb Company
Frances Heller will join as Senior VP, Business Development, on October 1...
28 September 2012 | By Abbott
The U.S. FDA has approved HUMIRA®...
27 September 2012 | By kdm communications limited
Deal marks Avacta’s entry to the third largest Asia-Pacific biotech market...
27 September 2012 | By CI Precision
Actelion Pharmaceuticals Ltd, has endorsed CI SADE weight sorters...
26 September 2012 | By GlaxoSmithKline
GSK announces the following changes to its Board and Committee structure...
26 September 2012 | By GlaxoSmithKline
Japanese New Drug Application (JNDA) submitted for COPD and asthma....
25 September 2012 | By Cisbio Bioassays
Cisbio Bioassays announces the launch of its epigenetics toolbox for use in drug discovery research...
25 September 2012 | By Boehringer Ingelheim / Eli Lilly & Company
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present data for three molecules, including two investigational compounds, from their Diabetes Alliance portfolio at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, 1–5 October 2012. Now in its second year, the Boehringer-Lilly Alliance…
24 September 2012 | By Renishaw plc
Celebrating 20 years of Renishaw Raman...
24 September 2012 | By Novo Nordisk
Novo Nordisk invests an additional 100 million US dollars to expand its state-of-the-art science facilities in Beijing....